Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0318344 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift PLOS ONE, 2025. Verfasst von Maryo Baakliny und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Est Créteil Val de Marne, Créteil, France. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, BNT162 Vaccine, Vaccine Efficacy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic with the continuous evolution of the virus into variants such as Alpha, Beta, Delta, Omicron and others necessitates an on-going surveillance and evaluation of vaccine effectiveness (VE).This study focuses on assessing the real-world performance of the Pfizer-BioNTech (BNT162b2) vaccine against the Omicron variant. This study employs a test-negative, case-control design, a methodology commonly utilized for estimating the VE in influenza studies. It evaluates SARS-CoV-2 test results in individuals aged 50 and older who had influenza-like illness (ILI) or COVID-like illness (CLI) symptoms and presented to the sentinel sites, classifying positive cases as “cases” and negative as “controls.” Data collection was done through a standardized questionnaire administered by the Epidemiological Surveillance Unit (ESU) COVID-19 team via phone interviews. Logistic regression analysis was performed to measure the association, taking into account all confounding factors. The results indicate a 14% VE against contracting the disease among fully vaccinated individuals. Factors such as age and underlying conditions significantly influenced VE. The findings of this study highlight the effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine in reducing the odds of symptomatic COVID-19, particularly by decreasing the prevalence of key symptoms such as fever, cough, myalgia, and loss of taste or smell. Breakthrough infections still occurred, indicating that while the vaccine reduces symptom severity, it may not fully prevent infection This VE is lower compared to previous variants, indicating potential challenges in vaccine efficacy. The study underscores the need for an on-going monitoring and potential booster doses to enhance protection, especially against evolving variants like Omicron.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris-Est Créteil Val de Marne, Créteil, France.
- Epidemiological Surveillance Unit, Ministry of Public Health, Beirut, Lebanon.
- INSPECT-LB (National Institute of Public Health, Clinical Epidemiology, and Toxicology-Lebanon), Beirut, Lebanon.
- Department of Epidemiology and Biostatistics, Faculty of Public Health, Lebanese University, Fanar, Lebanon.
ORCID-Profile: Maryo Baakliny
Zitieren
APA
Baakliny, M., Ghosn, N., Saleh, N., & Maison, P. (2025). Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022. PLOS ONE. https://doi.org/10.1371/journal.pone.0318344
Vancouver
Baakliny M, Ghosn N, Saleh N, Maison P. Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022. PLOS ONE. 2025. doi:10.1371/journal.pone.0318344
BibTeX
@article{Baakliny2025,
author = {Baakliny, Maryo and Ghosn, Nada and Saleh, Nadine and Maison, Patrick},
title = {Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0318344}
}
EUVIMED